• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

基于纳米病毒杀灭剂平台技术的生物聚合物（NV-CoV-2）的抗病毒活性机制

Mechanism of Antiviral Activities of Nanoviricide's Platform Technology based Biopolymer (NV-CoV-2).

作者信息

Chakraborty Ashok, Diwan Anil, Arora Vinod, Thakur Yogesh, Chiniga Vijetha, Tatake Jay, Pandey Rajesh, Holkar Preetam, Holkar Neelam, Pond Bethany

机构信息

Department of Biochemistry, AllExcel, Inc., 118, Wood Street, Ste 201, West Haven, CT 06516, USA.

Department of Virology, NanoViricides, Inc., 1, Controls Dr. Shelton, CT 06484, USA.

出版信息

AIMS Public Health. 2022 Apr 12;9(2):415-422. doi: 10.3934/publichealth.2022028. eCollection 2022.

DOI:10.3934/publichealth.2022028
PMID:35634020
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9114783/
Abstract

NV-CoV-2 is a nanoviricide that is covalently bonded with polyethylene glycol (PEG) and alkyl pendants. This molecular design is used to attack many strains of coronaviruses in a broad-spectrum manner. The ligand works by competitive inhibition and binds to the same site on the S-protein of SARS-CoV that attaches to the cognate cellular receptor, ACE2. This prevents SARS-CoV from binding and infecting the cell. NV-CoV-2 is designed to bind to the free virion particles at multiple points encapsulate the virus and disable its ability to infect the cells. The multi-point binding interaction, like a nano-velcro-tape, may lead to lipid-lipid fusion of the alkyl chains in the nanoviricide micelle with the lipid envelope of the virus. The virus becomes dismantled to a capsid form before the host immune system becomes involved. This putative mechanism is orthogonal to many other anti-coronavirus agents in development. Thus, it maybe possible to produce a stronger antiviral effect when combining NV-CoV-2 therapy with other anti-coronavirus therapies such as Remdesivir (RDV). NV-CoV-2 can encapsulate other antiviral compounds as well. In this study, RDV was encapsulated and protected from serum-mediated degradation . As a result, RDV was available for a longer period of time to interact with RNA polymerase and inhibit.

摘要

NV-CoV-2是一种与聚乙二醇（PEG）和烷基侧链共价结合的纳米病毒剂。这种分子设计用于以广谱方式攻击多种冠状病毒株。该配体通过竞争性抑制起作用，并与严重急性呼吸综合征冠状病毒（SARS-CoV）的S蛋白上与同源细胞受体血管紧张素转换酶2（ACE2）结合的相同位点结合。这可防止SARS-CoV结合并感染细胞。NV-CoV-2旨在在多个点与游离病毒粒子结合，包裹病毒并使其丧失感染细胞的能力。这种多点结合相互作用就像一条纳米魔术贴带，可能导致纳米病毒剂胶束中的烷基链与病毒的脂质包膜发生脂质-脂质融合。在宿主免疫系统参与之前，病毒就会解体为衣壳形式。这种假定的机制与许多其他正在研发的抗冠状病毒药物不同。因此，将NV-CoV-2疗法与其他抗冠状病毒疗法（如瑞德西韦（RDV））联合使用时，可能会产生更强的抗病毒效果。NV-CoV-2也可以包裹其他抗病毒化合物。在本研究中，RDV被包裹起来，免受血清介导的降解。结果，RDV可在更长时间内与RNA聚合酶相互作用并产生抑制作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8487/9114783/4b79ef8a2694/publichealth-09-02-028-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8487/9114783/616caf2cdcf8/publichealth-09-02-028-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8487/9114783/e10ebe83ec73/publichealth-09-02-028-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8487/9114783/78c10e80fee3/publichealth-09-02-028-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8487/9114783/4b79ef8a2694/publichealth-09-02-028-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8487/9114783/616caf2cdcf8/publichealth-09-02-028-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8487/9114783/e10ebe83ec73/publichealth-09-02-028-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8487/9114783/78c10e80fee3/publichealth-09-02-028-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8487/9114783/4b79ef8a2694/publichealth-09-02-028-g004.jpg

相似文献

1
Mechanism of Antiviral Activities of Nanoviricide's Platform Technology based Biopolymer (NV-CoV-2).基于纳米病毒杀灭剂平台技术的生物聚合物（NV-CoV-2）的抗病毒活性机制
AIMS Public Health. 2022 Apr 12;9(2):415-422. doi: 10.3934/publichealth.2022028. eCollection 2022.
2
Dual effects of NV-CoV-2 biomimetic polymer: An antiviral regimen against COVID-19.NV-CoV-2 仿生聚合物的双重作用：COVID-19 的抗病毒方案。
PLoS One. 2022 Dec 30;17(12):e0278963. doi: 10.1371/journal.pone.0278963. eCollection 2022.
3
Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.瑞德西韦是一种直接作用的抗病毒药物，能高效抑制严重急性呼吸综合征冠状病毒 2 的 RNA 依赖性 RNA 聚合酶。
J Biol Chem. 2020 May 15;295(20):6785-6797. doi: 10.1074/jbc.RA120.013679. Epub 2020 Apr 13.
4
The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.抗病毒化合物瑞德西韦能有效抑制中东呼吸综合征冠状病毒的 RNA 依赖性 RNA 聚合酶。
J Biol Chem. 2020 Apr 10;295(15):4773-4779. doi: 10.1074/jbc.AC120.013056. Epub 2020 Feb 24.
5
Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivir.高效掺入和模板依赖性聚合酶抑制是瑞德西韦广谱抗病毒活性的主要决定因素。
J Biol Chem. 2022 Feb;298(2):101529. doi: 10.1016/j.jbc.2021.101529. Epub 2021 Dec 23.
6
Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice.瑞德西韦在人肺细胞和表达 SARS-CoV-2 聚合酶的嵌合 SARS-CoV 小鼠中抑制 SARS-CoV-2。
Cell Rep. 2020 Jul 21;32(3):107940. doi: 10.1016/j.celrep.2020.107940. Epub 2020 Jul 7.
7
Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action.瑞德西韦对冠状病毒RNA依赖性RNA聚合酶的模板依赖性抑制揭示了第二种作用机制。
J Biol Chem. 2020 Nov 20;295(47):16156-16165. doi: 10.1074/jbc.AC120.015720. Epub 2020 Sep 23.
8
Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice.瑞德西韦在人肺细胞以及在小鼠中表达SARS-CoV-2 RNA聚合酶的嵌合SARS-CoV中能有效抑制SARS-CoV-2。
bioRxiv. 2020 Apr 27:2020.04.27.064279. doi: 10.1101/2020.04.27.064279.
9
Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.针对高融合活性新兴冠状病毒 SARS-CoV-2 的有效膜融合抑制剂设计。
J Virol. 2020 Jul 1;94(14). doi: 10.1128/JVI.00635-20.
10
Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection .基于人血管紧张素转化酶 2（ACE2）的订书肽强烈抑制 SARS-CoV-2 感染。
mBio. 2020 Dec 11;11(6):e02451-20. doi: 10.1128/mBio.02451-20.

引用本文的文献

1
Unlocking the potential of remdesivir: innovative approaches to drug delivery.释放瑞德西韦的潜力：药物递送的创新方法。
Drug Deliv Transl Res. 2025 Apr 17. doi: 10.1007/s13346-025-01843-7.
2
Nanotechnology-based theranostic and prophylactic approaches against SARS-CoV-2.基于纳米技术的 SARS-CoV-2 治疗和预防策略。
Immunol Res. 2024 Feb;72(1):14-33. doi: 10.1007/s12026-023-09416-x. Epub 2023 Sep 8.
3
Prospect of nanomaterials as antimicrobial and antiviral regimen.纳米材料作为抗菌和抗病毒疗法的前景。

本文引用的文献

1
Mechanisms of coronavirus cell entry mediated by the viral spike protein.冠状病毒刺突蛋白介导的病毒细胞进入机制。
Viruses. 2012 Jun;4(6):1011-33. doi: 10.3390/v4061011. Epub 2012 Jun 20.
2
The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2.人类冠状病毒NL63和严重急性呼吸综合征冠状病毒的S蛋白结合血管紧张素转换酶2的重叠区域。
Virology. 2007 Oct 25;367(2):367-74. doi: 10.1016/j.virol.2007.04.035. Epub 2007 Jul 12.
3
Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry.
AIMS Microbiol. 2023 May 10;9(3):444-466. doi: 10.3934/microbiol.2023024. eCollection 2023.
人冠状病毒NL63利用严重急性呼吸综合征冠状病毒受体进入细胞。
Proc Natl Acad Sci U S A. 2005 May 31;102(22):7988-93. doi: 10.1073/pnas.0409465102. Epub 2005 May 16.